Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.68 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 7/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10623902 | 0.81 | CA2 (0.66) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL11328699 | 0.81 | CA2 (0.68) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL10626668 | 0.81 | CA2 (0.68) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL17774980 | 0.80 | PTPN11 (0.67) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL13690232 | 0.80 | PTPN11 (0.67) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL7527132 | 0.78 | PTPN1 (0.66) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL7528321 | 0.77 | PTPN11 (0.79) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL3155581 | 0.76 | PTPN1 (0.63) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL4049597 | 0.76 | CA2 (0.67) | CA2PTPN11CA1PTPN1SMN1; SMN2 | |
| SCHEMBL6881190 | 0.76 | PTPN1 (0.63) | CA2PTPN11CA1PTPN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6472145-B2 | A MOBILE IONOPHORE COMPOSITION EFFECTIVE TO MODULATE APP CATABOLISM WITHOUT SUBSTANTIALLY ALTERING THE VIABILITY OF APP-CONTAINING CELLS; INHIBITS AMYLOID DEPOSITION; ALZHEIMER'S DISEASE; NONTOXIC | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-10-29 | — | — | US | claimed |
| US-20020045621-A1 | Method and composition for modulating amyloidosis | THE UNIVERSITY OF BRITISH COLUMBIA | 2002-04-18 | — | — | US | claimed |
| US-6221667-B1 | PACKAGED PHARMACEUTICAL COMPOSITION INCLUDES A MOBILE IONOPHORE WHICH PREVENTS OR DECREASES AMYLOID PRECURSOR PROTEIN CATABOLISM IN CELLS WITHOUT ALTERING CELL VIABILITY IN A PHARMACEUTICAL VEHICLE IN A CONTAINER, AND INSTRUCTIONS | THE UNIVERSITY OF BRITISH COLUMBIA | 2001-04-24 | — | — | US | claimed |
| EP-1077706-A1 | IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059597-A1 | IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1999-11-25 | — | — | WO | claimed |
| US-5981168-A | Method and composition for modulating amyloidosis | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1999-11-09 | — | — | US | claimed |
| US-6472145-B2 | A MOBILE IONOPHORE COMPOSITION EFFECTIVE TO MODULATE APP CATABOLISM WITHOUT SUBSTANTIALLY ALTERING THE VIABILITY OF APP-CONTAINING CELLS; INHIBITS AMYLOID DEPOSITION; ALZHEIMER'S DISEASE; NONTOXIC | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2002-10-29 | — | — | US | disclosed |
| US-20020045621-A1 | Method and composition for modulating amyloidosis | THE UNIVERSITY OF BRITISH COLUMBIA | 2002-04-18 | — | — | US | disclosed |
| US-6221667-B1 | PACKAGED PHARMACEUTICAL COMPOSITION INCLUDES A MOBILE IONOPHORE WHICH PREVENTS OR DECREASES AMYLOID PRECURSOR PROTEIN CATABOLISM IN CELLS WITHOUT ALTERING CELL VIABILITY IN A PHARMACEUTICAL VEHICLE IN A CONTAINER, AND INSTRUCTIONS | THE UNIVERSITY OF BRITISH COLUMBIA | 2001-04-24 | — | — | US | disclosed |
| EP-1077706-A1 | IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059597-A1 | IONOPHORE CONTAINING COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1999-11-25 | — | — | WO | disclosed |
| US-5981168-A | Method and composition for modulating amyloidosis | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045621-A1 | Method and composition for modulating amyloidosis | APP, PSEN1, PSEN2 | CA2 782/4885PTPN11 3796/4885CA1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.